Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s
Biochem Soc Trans 43:727733
These two flashpoints, Novos crackdown and Hims Super Bowl debut, frame a broader transformation: What happens when demand for affordable, personalized medicine outpaces the system built to regulate it
Determining when to stop depends on the specific medication, as they each stay in the body for different lengths of time
( D ) Mouse caSMCs were treated as above and lysed with PKA lysis buffer, with PKA activity determined by separation of phosphorylated (+ p-Peptag) and nonphosphorylated ( p-Peptag) substrate using electrophoresis